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Abstract
The role of urinary retinol-binding protein (RBP) as a biomarker of CKD in proximal tubular
diseases, glomerulopathies and in transplantation is well established. However, whether
urinary RBP is also a biomarker of renal damage and CKD progression in general CKD is
not known. In this study, we evaluated the association of urinary RBP with renal function
and cardiovascular risk factors in the baseline data of the Progredir Study, a CKD cohort in
Sao Paulo, Brazil, comprising 454 participants with stages 3 and 4 CKD. In univariate anal-
ysis, urinary RBP was inversely related to estimated glomerular filtration rate (CKD-EPI
eGFR) and several cardiovascular risk factors. After adjustments, however, only CKD-EPI
eGFR, albuminuria, systolic blood pressure, anemia, acidosis, and left atrium diameter
remained significantly related to urinary RBP. The inverse relationship of eGFR to urinary
RBP (β-0.02 ± 95CI -0.02; -0.01, p<0.0001 for adjusted model) remained in all strata of
albuminuria, even after adjustments: in normoalbuminuria (β-0.008 ± 95CI (-0.02; -0.001,
p = 0.03), in microalbuminuria (β-0.02 ± 95CI (-0.03; -0.02, p<0,0001) and in macroalbumi-
nuria (β-0.02 ± 95CI (-0.03; -0.01, p<0,0001). Lastly, urinary RBP was able to significantly
increase the accuracy of a logistic regression model (adjusted for sex, age, SBP, diabetes
and albuminuria) in diagnosing eGFR<35 ml/min/1.73m2 (AUC 0,77, 95%CI 0,72–0,81 ver-
sus AUC 0,71, 95%CI 0,65–0,75, respectively; p = 0,05). Our results suggest that urinary
RBP is significantly associated to renal function in CKD in general, a finding that expands
the interest in this biomarker beyond the context of proximal tubulopathies, glomerulopa-
thies or transplantation. Urinary RBP should be further explored as a predictive marker of
CKD progression.
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Introduction
Retinol binding protein (RBP) is a low molecular weight protein belonging to the lipocalin
super family [1] and mainly synthesized in the liver. Its main function is to transport retinol
(vitamin A). The majority of RBP-retinol circulates in the plasma bound to transthyretin
(TTR) [2], a complex that prevents its glomerular filtration. Conversely, 4–5% of serumRBP-
retinol circulates freely, pass the glomerular barrier and is then reabsorbed and degraded in the
proximal tubule, a process mediated by megalin [3]. Due to these properties, urinary RBP is an
established biomarker of proximal tubular dysfunction and is used as a diagnostic tool in proxi-
mal tubulopathies, such as Fanconi syndrome, Dent’s disease, cystinosis, or cast nephropathy.
Beyond the scenario of typical proximal tubulopathies, it has been shown that urinary RBP
is related to the risk of CKD progression in some other conditions. Studies from one center
have shown that higher values of urinary RBP are associated to disease activity, corticosteroid
resistance and risk of CKD in diverse glomerulopathies [4,5]. In renal transplant recipients, uri-
nary RBP has been positively associated to the risk of CKD [6], and in heart transplantation it
has been associated with the risk of cyclosporine toxicity and CKD [7]. However, despite these
promising initial results, urinary RBP has not been assessed in more prevalent CKD etiologies
or in larger samples of CKD patients. In diabetic kidney disease, one of the most common
causes of CKDworldwide, data are scarce, with few small cross-sectional studies in the 80´s
showing that urinary RBP was associated to surrogate markers of progression such as microal-
buminuria, HbA1c, and other parameters of microvascular disease [8–10].
Only recently, our group showed that urinary RBP was independently related to the risk of
creatinine duplication or renal replacement therapy (RRT) initiation in macroalbuminuric dia-
betic kidney disease [11]. Along with previous findings in the literature, this result led us to the
question whether urinary RBP could also work as a biomarker of CKD in conditions other
than proximal tubulopathies, glomerulopathies and transplantation.
In this sense, the aim of the present study was to test the hypothesis that urinary RBP is
associated with renal function in general CKD. For this we have evaluated the relationship
between urinary RBP and renal function and cardiovascular risk factors in the baseline data of
the Progredir Cohort Study, which comprehends stages 3 and 4 CKD participants. This cohort
was designed to reflectmore prevalent causes of CKD, by excluding primary and secondary
glomerulopathies in enrollment, as well as renal transplant patients.
Subjects and Methods
The present study was performed using the baseline data from the Progredir Cohort Study.
Briefly, patients fromHospital das Clinicas outpatient service, Sao Paulo, Brazil, a tertiary care
facility, were invited to participate in the study. Inclusion criteria were: age30 years-old and
at least two measurements of serum creatinine (with a minimum interval of 3 months)
1.6mg/dL for men and1.4mg/dL for women in a computer-screening including all ambula-
tory services. Exclusion criteria were: hospitalization in the last 6 months, acute myocardial
infarction in the last 6 months, autoimmune diseases, pregnancy, psychiatric diseases, ongoing
chemo or immunosuppressive therapy, ongoing RRT, glomerulonephritis,HIV/AIDS infec-
tion, C and B hepatitis, and any organ transplantation. Recruitment took place fromMarch
2012 to December 2013, and 454 participants were enrolled. The study was approved by two
local Ethics Committees and written informed consent was obtained from all participants.
Each participant visited the research center for interviews and clinical exams according to
standard protocols. Interview and clinical examination were performed by trained personal
under strict quality control. Participants were firstly submitted to anthropometric measures
using light clothes. Blood pressure (BP) was measured using a validated oscillometric device
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(Omron HEM 705CPINT). Three measurements were performed at 1-minute intervals and
the mean was calculated. Overnight fasting blood samples, 24hour and spot urine were col-
lected. A standard 75-g oral glucose tolerance test was administered to all participants without
known diabetes. Urine and blood aliquots were prepared and stored at -180°C in nitrogen.
Serumand urinary creatinine concentrations were determined by the Jaffé reaction and pro-
teinuria was determined by colorimetric assay (pyrogallol). Glomerular filtration rate was esti-
mated by the CKD-EPI [12] equation and 24h proteinuria was corrected for 1,73m2. Urinary
and serumRBP assays were performed by the laboratory of theHospital do Rim e Hipertensão
—Universidade Federal de São Paulo. Urinary RBP was measured using an immunoenzymatic
assay with monoclonal antibody and expressed as mg/g urinary creatinine, with a reference
range of 0.10–2.7 mg/g creatinine [13]. SerumRBP was measured using a test System for turbi-
dimetrywith a polyclonal rabbit anti-human RBP antibody (DAKO/ Biogen), with a reference
range of 26-60mg/L. Other laboratorial data were determined using conventional techniques.
Albumin and creatinine were also performed in spot urine to calculate albumin-to-creatinine
ratio (ACR). Normoalbuminuria was defined as an ACR  30μg/mg creatinine, microalbumi-
nuria was defined as an ACR 30–300μg/mg creatinine and macroalbuminuria 300μg/mg
creatinine.
Transthoracic echocardiography was performed using an Aplio XG; Toshiba Corporation,
Tokyo, Japan, with a 2.5 MHz sector transducer. The readings consisted of qualitative analysis
of echocardiographic findings and measurements of quantitative parameters. The carotid-fem-
oral pulse wave velocity (PWV) was measured using a validated automated device (Complior,
ArtechMedicale, France) with the subject in the supine position. Intima media thickness
(IMT) was measured in the outer wall of a pre-defined carotid segment of 1 cm in length from
1 cm below carotid bifurcation, during three cardiac cycles.We considered as valid acquired
images that clearly visualized on both sides three reference points: (1) the anatomic guides for
the common carotid arteries, (2) interfaces between the lumen and the vessel far wall and (3)
interfaces between the media and the adventitia layers of the far vessel wall. We usedMIA™
software to standardize the reading and interpretation of carotid scans.
For coronary artery calcium score, the participants underwent a non-contrast computed
tomography. The scans were performed using a 64 detector computed tomography scanner
(Philips Brilliance, Philips, Netherlands). After the scout images, each patient also underwent
an ECG-gated prospective calcium score examination with a tube potential of 120 kV and a
tube current adjusted to body habitus. Images were reconstructed in 2.5 mm slice thickness
using standard filtered back projection. The CAC was expressed as Agatston units and the per-
centile was evaluated in a blinded fashion by an experienced cardiologist using semiautomatic
software (Calcium Scoring, Philips Workstation). Patients with coronary stents were excluded
from these analyses. CAC severity was further categorized as 0 or>0 and<100 or100. [14]
Statistical analysis
For descriptive analysis the variables were divided according to tertiles of urinary RBP.
ANOVA and Kruskal—Wallis tests were performed for comparison of continuous variables,
and the chi-square test was performed for comparison of categorical variables. For linear
regression analyses, urinary RBP was log transformed. In our sample, CAC presented an asym-
metric distribution instead of the characteristic zero-inflated distribution reported in non-
CKD populations. Thus, generalized regression models on CAC using a gamma model were
used to model this variable. Lastly, logistic regression models were built for the diagnosis of
CKD-EPI eGFR<35 ml/min/1.73m2 and ROC curves of the probabilities of each model were
compared (http://vassarstats.net/roc_comp.html). Statistical analyses were conducted using
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SPSS 17.0 software for Windows (SPSS, Inc.) and R software (calcification). All tests were two-
tailed and a p value of 0.05 was considered significant.
Results
Table 1 shows the baseline clinical and laboratorial variables for all participants according to
tertiles of urinary RBP. Urinary RBP was inversely associated to renal function and positively
associated to diabetes, female gender, systolic blood pressure, albuminuria, glycated hemoglo-
bin, total-cholesterol, HDL-cholesterol, and PWV. Other parameters related to uremia such as
anemia, acidosis and mineral metabolismwere also associated to urinary RBP. Interestingly,
urinary RBP was inversely associated with left atrium diameter and ejection fraction, as well as
with self-reported history of acute myocardial infarction. No relationship between urinary RBP
and carotid thickness was found. The relationship between urinary RBP and calcium score was
assessed using gamma models. Although a positive association appeared in the univariate anal-
ysis, statistical sigificancewas lost after adjustments for age, sex, eGFR and diabetes were made
(not shown).
Next, we performed several multivariate models on urinary RBP (log transformed due to
very skewed distribution), shown in Table 2. In the first models (Model 1), which were adjusted
only for sex, age and CKD-EPI eGFR,most variables from Table 1 remained associated to uri-
nary RBP. However, in Model 2, adjusted for the same variables than Model 1 plus diabetes
and SBP, urinary RBP remained positively associated to albuminuria, serum phosphorus,
HDL-cholesterol and PWV, and inversely associated to CKD-EPI eGFR, bicarbonate, serum
albumin and left atrium diameter. In Model 3, all variables fromModel 1 were used in a step-
wise forward procedure and only CKD-EPI eGFR, albuminuria, left atrium diameter, SBP and
bicarbonate remained significantly and independently associated to urinary RBP.
We then performed stepwise linear regression on urinary RBP after stratification of partici-
pants according to albuminuria categories (normo, micro and macroalbuminuria). In all strata,
CKD-EPI eGFR remained in the model, showing an inverse and significant association with
urinary RBP (Table 3).
Lastly, we classified participants according to a CKD-EPI eGFR cut-off of 35 ml/min/
1,73m2. We performed two logistic regression models for the diagnosis of a CKD-EPI eGFR
<35 ml/min/1,73m2: one adjusting for sex, age, diabetes, SBP and albuminuria and the second
adjusting for sex, age, diabetes, SBP, albuminuria and urinary RBP. Fig 1 shows that the model
including urinary RBP had a better performance than the model without urinary RBP (p = 0,05
for non-parametric test comparing the two models).
Discussion
Our results suggest that urinary RBP is significantly and inversely associated to renal function,
even after adjustments for several confounding variables. Besides showing a consistent and
independent relation to renal function in all analysis performed, urinary RBP added accuracy
for predicting low eGFR in this cross-sectional analysis in comparison to a model adjusted for
the most important and traditional risk factors for CKD, including albuminuria.
In the Progredir Study, glomerulonephritis and transplantation were not included and prox-
imal tubulopathies account for a very low prevalence in general CKD. By showing that urinary
RBP associates consistently with renal function in this scenario, our results indicate that uri-
nary RBP may work as a biomarker of CKD in general, a performance beyond the three classi-
cal pathological conditions that have been previously shown to be associated with urinary RBP.
In addition, the association between eGFR and urinary RBP remained significant in all
strata of albuminuria. This is particularly important in the setting of normoalbuminuric CKD,
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since this is a population in whom no laboratorial biomaker besides renal function itself is
available. Albuminuria has been widely used as a surrogate marker of CKD. Nonetheless, it has
been recognized that around 30% of CKD patients may present in fact a normoalbuminuric
disease [15] and that renal function declinemay precede evolution to macroalbuminuria and
Table 1. Baseline clinical and laboratorial variables for all participants and according to urinary RBP tertiles.
All Tertile 1-uRBP Tertile 2-uRBP Tertile 3-uRBP p
n = 454 n = 144 n = 144 n = 144
Age (years; mean / std) 67.5 11.9 67.5 12 67.8 11.3 66.5 12.4 0.64
Sex (men; n / %) 287 63.2% 108 75% 83 57.6% 84 58.3% 0.002
Race (white; n/ %) 300 66.1% 90 62.5% 97 67.8% 98 69.5% 0.42
Hypertension (n/ %) 409 90.1% 131 91% 125 87.4% 135 93.8% 0.18
Diabetes (n/ %) 208 45.8% 53 36.8% 72 50.3% 76 53.1% 0.04
Acute myocardial infarction (n/ %) 147 32.4% 47 32.9% 52 36.4% 44 30.8% 0.004
Stroke (n/ %) 73 16.1% 27 19.1% 30 21.4% 15 10.8% 0.09
Systolic blood pressure (mmHg; mean / std) 140 24.1 133.1 20.3 140.3 25.1 146.3 24.3 <0,0001
Diastolic blood pressure (mmHg; mean / std) 76.2 12.9 74.2 12.3 76.5 13.6 77.5 12.2 0.08
Body-mass index (mean / std) 29.4 5.4 30.3 6.5 29.1 4.6 29 5.1 0.11
Potassium (mEq/L; mean / std) 4.6 0.5 4.6 0.5 4.5 0.5 4.7 0.5 0.001
Urea (mg/dL; median/ IQR) 69 54–89 63 50–89 64 51–79 80 63,5–97 <0,0001
Creatinine (mg/dL;median / IQR) 1.7 1,4–2,1 1.6 1,3–1,9 1.5 1,3–1,8 2.1 1,7–2,6 <0,0001
Albuminuria (mg/g creat; median / IQR) 80 15–640 17 11–119 61 21–310 654 94–1759 <0,0001
Urinary RBP (mg/g creat; median / IQR) 0.29 0,08–1,47 0.05 0,03–0,08 0.29 0,18–0,42 3.09 1,47–10,69 <0,0001
CKD-EPI eGFR (ml/min/1.73 m2 mean / std) 38.4 14.6 42.5 15.7 43.0 13.6 29.5 10.7 <0,0001
Phosphorus (mg/dL; mean / std) 3.6 0.6 3.6 0.7 3.6 0.6 3.8 0.6 <0,0001
Calcium (mg/dL; mean / std) 9.6 0.6 9.5 0.6 9.6 0.5 9.5 0.6 0.16
Parathormone (pg/mL; median / IQR) 93 64–143 88 55–136 88 63,5–126 114 77–184 0.001
Serum RBP (mg/L; median / IQR) 66.1 55,2–79,8 63.3 51,1–77,6 60.5 53,9–78,3 75 62,1–85,7 <0,0001
Glycemia (mg/dL;median / IQR) 104 95–126 102 95,0–120,5 108.5 94,5–129,5 107.5 92,5–136 0.69
Glycated hemoglobin (%; median / IQR) 6.2 5,8–7,2 6.1 5,7–6,7 6.3 5,8–7,5 6.4 5,9–7,7 0.003
OGTT (mg/dl; mean / std)* 155 51.8 163 52.7 145.1 48.1 155.1 54.5 0.13
HOMA-IR (mediana/ IQ)* 3.4 2,3–5,8 4.2 2,4–6,5 2.9 2,2–5,0 2.8 2,2–5,3 0.02
Insulinemia (μUI/mL; IQ) 16.1 10,4–25,4 17.1 10,9–26,6 16.4 11,4–25,5 14.5 9,8–24,6 0.30
Total cholesterol (mg/dL mean / std) 168.6 39.9 161.9 35.3 169.8 42.6 173.6 41.7 0.04
LDL-cholesterol (mg/dL; mean / std) 91.4 32.2 89 28.4 90.3 35.4 93.9 33.1 0.42
HDL-cholesterol (mg/dL; mean / std) 46 14.3 42.9 10.8 47.2 17.6 47.7 13.7 0.007
Triglycerides (mg/dL; median / IQR) 142 99–192 143 101,5–188 141 99,5–204 141 94,0–196,5 0.89
Serum pH (mean / std) 7.4 0.039 7.4 0.040 7.4 0.037 7.3 0.038 <0,0001
Bicarbonate (mmol/L; mean / std 25.6 2.9 25.9 3.0 26.1 2.7 24.6 2.9 <0,0001
Hemoglobin (g/dL; mean / std) 13.1 1.9 13.5 2.0 13.2 1.7 12.7 1.9 0.003
Albumin (mg/dL; mean / std) 4.3 0.3 4.3 0.3 4.4 0.3 4.2 0.3 0.001
Pulse wave velocity (cm/s; mean / std) 12.8 3.0 12.1 3.1 12.5 2.8 13.6 2.8 <0,0001
Left atrium diameter (mm; mean / std) 41.4 5.4 42.5 5.6 41.7 6.2 40.2 4.1 0.001
Ejection fraction (median / IQR) 0.7 0,6–0,7 0.62 0,53–0,69 0.67 0,58–0,70 0.67 0,6–0,70 <0,0001
Intima media thickness (mm; mean / std) 0.75 0.20 0.77 0.24 0.73 0.19 0.73 0.18 0.13
Agatston score (median / IQR) 165 8–785 134 8–635 174 2–1002 166 2,5–786 0.76
Agatston>100 (n/%) 205 55.1% 63 53.8% 62 54.4% 69 55.6% 0.96
* calculated for participants without known diabetes
doi:10.1371/journal.pone.0162782.t001
Urinary RBP in Chronic Kidney Disease
PLOS ONE | DOI:10.1371/journal.pone.0162782 September 21, 2016 5 / 10
occurs in 10% of normoalbuminurics and 35% of microalbuminuria type 1 diabetic patients
[16].
These results raise the question of why urinary RBP can be a marker of CKD in general.
One hypothesis is that by being related to proximal tubular function, urinary RBP might reflect
tubule-interstitial fibrosis, which is a well-recognizedand powerful histologic predictor of
CKD. A recent study showed that urinary RBP was correlated to the extent of interstitial fibro-
sis in kidney biopsies from 189 patients with various etiologies of CKD (glomerular, interstitial
and vascular diseases) [17]. Unfortunately, in our study, we could not evaluate this hypothesis,
since kidney biopsy is not routinely performed in CKD. Another possibility is that RBP
Table 2. Linear regression models on log urinary RBP.
B Std. Error 95%CI p
Model 1: adjusted for sex, age and CKD-EPI eGFR
CKD-EPI eGFR (ml/min/1.73 m2) -.026 .003 -.031 -.021 <0,0001
Diabetes .238 .076 .089 .387 .002
Acute myocardial infarction -.063 .091 -.242 .116 .49
SBP (mmHg) .009 .002 .006 .012 <0,0001
Albuminuria (mg/g creat) .0002 .00003 .0001 .0003 <0,0001
Glycated hemoglobin (%) .071 .027 .019 .124 .01
HOMA-IR* -.025 .016 -.056 .006 .12
Serum RBP (mg/L) .0001 .002 -.003 .003 .93
Total cholesterol (mg/dL) .001 .001 -.001 .003 .42
HDL-cholesterol (mg/dL) .007 .003 .001 .012 .01
Potassium (mEq/L) .085 .078 -.067 .238 .27
Phosphorus (mg/dL) .145 .064 .019 .272 .02
Parathormone (pg/mL) -.0001 .0004 -.001 .001 .85
Bicarbonate (mmol/L) -.037 .014 -.064 -.010 .01
Hemoglobin (g/dL) -.020 .024 -.066 .027 .40
Albumin (mg/dL) -.272 .127 -.521 -.022 .03
Pulse wave velocity (cm/s) .053 .015 .024 .083 <0,0001
Left atrium diameter (mm) -.015 .007 -.029 -.0001 .05
Ejection fraction .535 .293 -.042 1.111 .07
Model 2: adjusted for sex, age and CKD-EPI eGFR, diabetes and SBP
CKD-EPI eGFR (ml/min/1.73 m2) -.024 .003 -.029 -.019 <0,0001
Albuminuria (mg/g creat) .0001 .00003 .0001 .0002 <0,0001
Phosphorus (mg/dL) .121 .062 -.002 .243 .05
HDL-cholesterol (mg/dL) .008 .003 .002 .013 .01
Bicarbonate (mmol/L) -.040 .013 -.066 -.014 .002
Albumin (mg/dL) -.187 .122 -.428 .053 .13
Pulse wave velocity (cm/s) .020 .016 -.012 .052 .23
Left atrium diameter (mm) -.014 .007 -.028 -.0002 .05
Model 3: all variables from model 1, stepwise forward
CKD-EPI eGFR (ml/min/1.73 m2) -.020 .003 -.025 -.014 <0,0001
Albuminuria (mg/g creat) .0002 .00003 .0001 .0002 <0,0001
Left atrium diameter (mm) -.024 .007 -.038 -.010 .001
SBP (mmHg) .006 .002 .003 .009 .001
Bicarbonate (mmol/L) -.038 .013 -.064 -.012 .005
*calculated only for those without diabetes
doi:10.1371/journal.pone.0162782.t002
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appearance in urine indicates a failure in one of the mechanisms related to proximal tubule
function. In physiological conditions, urinary RBP is expected to be<0,4mg/g creatinine.
Higher levels may occur in three conditions: (1) due to an impairment in the glomerular filtra-
tion barrier, as occurs in nephrotic syndrome, (2) when there is massive production of low
molecular weight protein, overcoming the capacity of proximal tubular reabsorption, as seen in
cast nepropathy or (3) in conditions where a direct impairment in the reabsorptionmachinery
is the phenotype, as occurs in Dent´s disease and cystinosis. All these mechanisms (particularly
the first and third) might be operating in several etiologies of CKD, hinting on why urinary
RBP can have an overall good performance in CKD in general.
Table 3. Stepwise linear regression models on log urinary RBP stratified by albuminuria categories (normo, micro and macroalbuminuria)
among 454 participants.
B Std. Error 95%CI p
Normoalbuminuria (n = 155)
Sex (men) -.255 .108 -.468 -.042 .02
Diabetes .306 .102 .104 .508 .003
CKD-EPI eGFR (ml/min/1.73 m2) -.008 .004 -.015 -.001 .03
Microalbuminuria (n = 136)
CKD-EPI eGFR (ml/min/1.73 m2) -.023 .004 -.031 -.015 <0,0001
SBP (mmHg) .006 .002 .001 .011 .01
Macroalbuminuria (n = 150)
CKD-EPI eGFR (ml/min/1.73 m2) -.020 .005 -.030 -.010 <0,0001
doi:10.1371/journal.pone.0162782.t003
Fig 1. ROC curves for two models (with and without urinary RBP) for diagnosis of CKD-EPI
eGFR<35ml/min/1.73m2 among 454 participants.
doi:10.1371/journal.pone.0162782.g001
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Another interesting findingwas the inverse association betweenurinaryRBP and left atrium
diameter. Curiously, this result was in the opposite direction of the relationship found for uri-
nary RBP and SBP or PWV. Unfortunately, we could not further investigate the reasons for
this. One hypothesis is that urinary RBP might discriminate to some extent pre-glomerular
insults from intrinsic renal insults (glomerular, tubular) that predominate in diseases such as
diabetic kidney disease, chronic interstitial nephritis, among others. In this sense, it would be
interesting not only to evaluate if this inverse association between urinary RBP and left atrium
diameter is confirmed in other CKD studies, but also test if urinary RBP can discriminate type
2 and type 4 cardio-renal syndromes [18–20].
SerumRBP and urinary RBP showed a positive association. It has been previously proposed
that high levels of urinary RBP could be a consequence of high serumRBP levels [21,22].
RBP4, which accounts for almost the total content of circulating RBP, has been recently recog-
nized as an adipocine, and is related to insulin resistance, obesity, diabetes and fat mass [23–
26]. Thus, RBP4 could confound the relationship between urinary RBP and renal function or
cardiovascular risk factors. In addition, decreasing eGFR is related to increasing serumRBP, a
fact that could contribute to this confounding effect. Once adjustments were made, with a par-
ticular emphasis on renal function, the positive association between serum and urinary RBP
was no longer significant. In addition, the other relationships described in the manuscript were
also independent of the effect of serumRBP.
Our study has some important limitations. First, data is cross-sectional. To better under-
stand how much information urinary RBP can add as a biomarker of CKD and CKD progres-
sion it would be important to test its performance in prospective studies and also in earlier
stages of the disease. Progredir Cohort follow-up is ongoing and we will evaluate the role of uri-
nary RBP in relation to clinical events in the near future. Second, as in other CKD cohorts, his-
tological data is not available, since most patients with CKD (particularly considering the
inclusion and exclusion criteria used in the Progredir Study) are not candidates to kidney
biopsy. Thus, we could not test some hypothesis raised by our results. Third, we did not mea-
sure other tubular markers. It would be interesting to compare the performance of urinary
RBP to those of other markers related to tubular function.
In conclusion, our results suggest that urinary RBP is significantly associated to renal func-
tion in general CKD and should be further explored as a predictive and independent marker of
CKD progression.
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